United Therapeutics Corporation ($UTHR) Stock Forecast: Up 5.0% Today

What is United Therapeutics Corporation?

United Therapeutics Corporation is a biotechnology company developing innovative solutions for unmet medical needs. The company recently reported strong quarterly earnings, surpassing EPS estimates, and aims to tackle critical medical challenges.

Why is United Therapeutics Corporation going up?

UTHR stock is up 5.0% on Jan 6, 2026 15:21

• Today's positive movement in UTHR stock is linked to the company's Chairperson and CEO speaking at the J.P. Morgan Healthcare Conference, underlining their dedication to innovation and addressing medical needs.
• Institutional investors, including Merit Financial Group LLC and Allspring Global Investments Holdings LLC, have increased their stake in the company, showing confidence in its future growth despite recent insider transactions.
• An analysis of the rotational strategy timing suggests short-term sentiment may be weak. However, the focus remains on UTHR's long-term potential and fundamentals, indicating investors are looking beyond immediate fluctuations.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation announced that its Chairperson and Chief Executive Officer, Dr. Martine Rothblatt, will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via a live webcast on the company's investor relations website, with an archived version available for 30 days afterward. The company will discuss its mission to innovate for unmet medical needs and its public benefit corporation status.

https://ir.unither.com/press-releases/2026/01-05-2026-120012250

How United Therapeutics Corporation (UTHR) Affects Rotational Strategy Timing

This article analyzes United Therapeutics Corporation (UTHR) for rotational strategy timing, highlighting weak near-term sentiment despite potential long-term strength. It details specific institutional trading strategies, including long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis. The analysis provides key support and resistance levels across different time horizons for UTHR.

https://news.stocktradersdaily.com/news_release/101/How_United_Therapeutics_Corporation_UTHR_Affects_Rotational_Strategy_Timing_010326054002_1767480002.html

United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC

Merit Financial Group LLC has significantly increased its stake in United Therapeutics Corporation (UTHR), boosting its holdings by 56.3% in the third quarter to 7,416 shares valued at approximately $3.11 million. This comes as United Therapeutics reported strong Q3 earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $505. However, the company has also seen substantial insider selling recently, with insiders disposing of over 618,000 shares worth around $288 million in the past 90 days.

https://www.marketbeat.com/instant-alerts/filing-united-therapeutics-corporation-uthr-shares-bought-by-merit-financial-group-llc-2026-01-03/

Allspring Global Investments Holdings LLC Acquires 4,944 Shares of United Therapeutics Corporation $UTHR

Allspring Global Investments Holdings LLC has increased its stake in United Therapeutics (NASDAQ: UTHR) by 5.8%, now owning 89,809 shares valued at $39.35 million. While institutional ownership is high at 94.08% and analysts rate the stock a "Moderate Buy" with an average target of $505, there has been significant insider selling, totaling $287.9 million in the last 90 days. The biotechnology company recently beat EPS expectations but slightly missed revenue estimates, maintaining a strong net margin of 40.65%.

https://www.marketbeat.com/instant-alerts/filing-allspring-global-investments-holdings-llc-acquires-4944-shares-of-united-therapeutics-corporation-uthr-2026-01-03/

VIRGINIA RETIREMENT SYSTEMS ET Al Sells 137,900 Shares of United Therapeutics Corporation $UTHR

Virginia Retirement Systems et al significantly reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by selling 137,900 shares, decreasing its holdings by 71.1%. This divestment is part of broader insider selling activity, with COO Michael Benkowitz and other insiders selling a substantial number of shares recently. Despite this, United Therapeutics reported a quarterly EPS beat and maintains a "Moderate Buy" consensus rating from analysts.

https://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-sells-137900-shares-of-united-therapeutics-corporation-uthr-2026-01-01/

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 15.6% Today

Axie Infinity ($AXS) Crypto Forecast: Up 11.0% Today

Bittensor ($TAO) Crypto Forecast: Up 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 16.9% Today

Halliburton Company ($HAL) Stock Forecast: Up 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 6.8% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 6.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.3% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 18.5% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 20.0% Today

United Therapeutics Corporation Price History

06.00.2026 - UTHR Stock was up 5.0%

• Today's positive movement in UTHR stock is linked to the company's Chairperson and CEO speaking at the J.P. Morgan Healthcare Conference, underlining their dedication to innovation and addressing medical needs.
• Institutional investors, including Merit Financial Group LLC and Allspring Global Investments Holdings LLC, have increased their stake in the company, showing confidence in its future growth despite recent insider transactions.
• An analysis of the rotational strategy timing suggests short-term sentiment may be weak. However, the focus remains on UTHR's long-term potential and fundamentals, indicating investors are looking beyond immediate fluctuations.

26.01.2025 - UTHR Stock was down 8.1%

• Despite United Therapeutics surpassing Q4 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• Investors might have been disappointed with the company's future guidance or outlook, leading to a sell-off of the stock.
• The market may have reacted negatively to key metrics that fell short of Wall Street projections, causing a decline in UTHR's stock price.

09.03.2025 - UTHR Stock was down 5.7%

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

07.04.2025 - UTHR Stock was up 5.2%

• A dispute filed by United Therapeutics against Liquidia was dismissed by the District Court.
• UTHR's Q1 earnings and revenues exceeded estimates, driven by increased Tyvaso sales.
• The favorable legal outcome and strong financial results are believed to have influenced the bullish movement in UTHR's stock price today.

01.07.2025 - UTHR Stock was up 5.1%

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

02.08.2025 - UTHR Stock was up 0.8%

• Following the announcement of an expanded collaboration with MannKind Corporation for a second inhaled therapy, United Therapeutics (UTHR) witnessed a notable increase in its stock price. This development likely instilled confidence in investors regarding the company's growth potential and the possibility of new revenue streams.
• The positive market response could also be linked to the upcoming earnings report of United Therapeutics, adding to the optimistic outlook for the company's financial performance. As the stock continues to rise, investors appear hopeful about its future prospects.
• Today's bullish movement in UTHR's stock reflects the favorable progress in collaboration initiatives and the market's optimistic view of the company's future in the pharmaceutical sector.

30.06.2025 - UTHR Stock was down 5.4%

• UTHR reported Q2 earnings that missed analyst estimates on both the top and bottom lines, leading to a bearish movement in the stock.
• The company's announcement of a share repurchase program of up to $1 billion did not seem to offset the disappointment from the earnings miss.
• The stock crossing above the 50-day moving average could have initially signaled a positive trend, but the earnings results likely overshadowed this technical indicator, causing the bearish movement.
• Investors may be concerned about the company's future performance based on the Q2 results, leading to a sell-off in the stock.

29.09.2025 - UTHR Stock was up 8.3%

• UTHR experienced a strong bullish movement today by surpassing Q3 earnings estimates, exceeding expectations by 3.92%.
• The anticipation of earnings growth leading up to the upcoming report has likely bolstered the positive sentiment, showcasing faith in the company's future performance.
• Investors appear hopeful about UTHR's prospects, given its consistent delivery of favorable outcomes and ability to meet market expectations, resulting in an increase in the stock price.

10.05.2025 - UTHR Stock was down 10.7%

• UTHR's bearish movement could be attributed to profit-taking by investors after a period of growth or due to concerns about the company's future performance.
• The potential struggles of Corcept (CORT) after their last earnings report may have had a spillover effect on UTHR, causing investors to be cautious about the biotechnology sector as a whole.
• Investors might be reevaluating their positions in biotech stocks, leading to a broader sell-off in the sector and impacting UTHR negatively.
• It is essential for investors to closely monitor both company-specific news and industry trends to make informed decisions in the volatile biotechnology market.

30.06.2025 - UTHR Stock was down 4.2%

• UTHR stock witnessed a significant decline in value today.
• Falling short of Q2 earnings estimates by -5.74% potentially influenced the downward trajectory.
• Although surpassing the 50-day moving average, investors' response to the earnings disappointment likely drove the negative trend.
• Investor sentiment concerning UTHR may be influenced by apprehensions regarding future performance following the recent earnings outcome.

30.03.2025 - UTHR Stock was up 2.1%

• UTHR's strong bullish movement today can be attributed to the company's impressive Q1 earnings and revenue results, surpassing analyst estimates by 5.41% and 9.39% respectively. This positive financial performance likely instilled confidence in investors, driving up the stock price.
• Despite the overall bullish market movement, it's interesting to note that there were downgrades from a top analyst, which could have initially caused some uncertainty. However, the market seemed to focus more on the robust earnings report, overshadowing the analyst's revised outlook.
• The market's reaction indicates that investors placed more weight on UTHR's solid financial fundamentals rather than the analyst's downgrade, showcasing the significance of strong earnings in influencing stock price movements.

29.09.2025 - UTHR Stock was up 9.7%

• UTHR stock showed a strong bullish movement today, likely influenced by the company surpassing Q3 earnings expectations.
• Despite revenues falling below projections, the robust performance of Tyvaso and Orenitram contributed to the positive earnings surprise.
• Investor optimism regarding potential growth opportunities in the coming quarters may be fueled by the earnings beat.
• Market trends indicate that investors are more focused on the positive earnings surprise and growth potential, overshadowing the revenue shortfall and driving the bullish momentum in UTHR stock.